Stephen L Karr

US Patent:

6861510, Mar 1, 2005

Filed:

Jun 6, 1995

Appl. No.:

08/465917

Inventors:

Philip C. Gevas - Honolulu HI, US
Stephen L. Karr - Davis CA, US
Stephen Grimes - Davis CA, US
Richard L. Littenberg - Kai Lua HI, US

Assignee:

Aphton Corporation - Woodland CA

International Classification:

C07K016/00
C12P021/08
A61K039/395
A61K039/40
A61K039/42

US Classification:

5303881, 53038824, 53038815, 530386, 5303871, 530326, 530327, 530328, 530329, 530330, 4241841, 4241301, 4241411, 4241421

Abstract:

Immmunogenic compositions useful for the treatment of ulcers or tumors whose growth is dependent on or stimulated by gastrin hormones are disclosed. The immunogenic compositions induce antibodies in a subject which selectively neutralize the specific hormones. Pharmaceutical compositions comprising effective amounts of the immunogenic compositions and methods of treatment using the compositions are disclosed. A method of reversing the inventive treatments by neutralizing the antibodies induced in vivo is also disclosed.

US Patent:

8343930, Jan 1, 2013

Filed:

Jan 25, 2010

Appl. No.:

12/693127

Inventors:

Philip C. Gevas - Key Biscayne FL, US
Stephen Grimes - Davis CA, US
Stephen L. Karr - Davis CA, US
Susan A. Watson - Nottingham, GB
Dov Michaeli - Larkspur CA, US

Assignee:

Cancer Advances, Inc. - Durham NC

International Classification:

A61K 38/00

US Classification:

514 193

Abstract:

The present invention relates to a combination therapy method for treating gastrin-dependent tumors. The method comprises the immunization of a patient with an anti-gastrin 17 immunogenic composition in combination with the administration of chemotherapeutic agents such as 5-fluorouracil and leucovorin.

US Patent:

20020095028, Jul 18, 2002

Filed:

Mar 15, 2002

Appl. No.:

10/098690

Inventors:

Stephen Grimes - Davis CA, US
Stephen Karr - Davis CA, US

International Classification:

C07K014/00
C07K001/00
B01D017/00

US Classification:

530/412000, 422/287000

Abstract:

A system is described for conjugating, isolating, and purifying proteins. The system contains an ultrafiltration apparatus which is connected with a reaction vessel reservoir.

US Patent:

20030068326, Apr 10, 2003

Filed:

Dec 6, 2002

Appl. No.:

10/314057

Inventors:

Philip Gevas - Key Biscayne FL, US
Stephen Grimes - Davis CA, US
Stephen Karr - Davis CA, US
Dov Michaeli - Larkspur CA, US

Assignee:

Aphton Corporation - Miami FL

International Classification:

A61K039/00
A61K038/17

US Classification:

424/185100, 514/012000

Abstract:

A method for the treatment of gastroesophageal reflux disease comprising a combination of active immunization with an anti-gastrin immunogenic composition with an antagonist which blocks or inhibits the gastric acid pump activity; or alternatively administering purified anti-gastrin antibodies with a Hantagonist or proton pump inhibitor of the gastric acid producing enzyme system.

US Patent:

20050025770, Feb 3, 2005

Filed:

Jan 20, 2004

Appl. No.:

10/762226

Inventors:

Philip Gevas - Honolulu HI, US
Stephen Karr - Davis CA, US
Stephen Grimes - Davis CA, US
Dov Michaeli - Larkspur CA, US
Susan Watson - Nottingham, GB

International Classification:

A61K039/395

US Classification:

424155100

Abstract:

A method of treating gastrointestinal cancers dependent on the prohormones amidated gastrin-and glycine extended G-, comprising the administration to the patient of an anti-gastrin immunogen which induces antibodies which bind and neutralize amidated and glycine-extended gastrin-

US Patent:

20050187152, Aug 25, 2005

Filed:

Apr 21, 2004

Appl. No.:

10/829137

Inventors:

Philip Gevas - Key Biscayne FL, US
Stephen Grimes - Davis CA, US
Stephen Karr - Davis CA, US
Dov Michaeli - Larkspur CA, US
Susan Watson - Edwalton, GB

Assignee:

Aphton Corporation - Miami FL

International Classification:

A61K038/17
A61K031/4439
A61K031/4172

US Classification:

514012000, 514338000, 514400000

Abstract:

Serum-associated hypergastrinemia is treated by administration of gastrin active or passive immunization. An anti-gastrin immunogenic composition containing a gastrin G17 or G34 peptide fragment which is amino acid spacer-linked to an immunogenic carrier, is administered so as to effectively neutralize the circulating gastrin hormone, and moreover, inhibit autocrine activity by progastrin such as Gly-extended G17, and amidated G17, in patients with pernicious anemia. Moreover, the method includes administration of a therapeutically effective amount of anti-G17 or anti-G34 antibodies which may be in humanized form. Finally, the method provides ameliorating treatment of hypergastrinemic effects of proton pump inhibitors or Hhistamine receptor blocking agents or antagonists, in addition to treatment of hypergastrinemia caused by diseases such as pernicious anemia.

US Patent:

20060039911, Feb 23, 2006

Filed:

Oct 18, 2005

Appl. No.:

11/252904

Inventors:

Philip Gevas - Key Biscayne FL, US
Stephen Grimes - Davis CA, US
Stephen Karr - Davis CA, US
Dov Michaeli - Larkspur CA, US

Assignee:

Aphton Corporation - Philadelphia PA

International Classification:

A61K 39/395
A61K 38/22

US Classification:

424145100, 514012000

Abstract:

A method for the treatment of gastroesophageal reflux disease comprising a combination of active immunization with an anti-gastrin immunogenic composition with an antagonist that blocks or inhibits gastric acid pump activity; or alternatively administering purified anti-gastrin antibodies with an Hantagonist or proton pump inhibitor of the gastric acid producing enzyme system.

US Patent:

20090191232, Jul 30, 2009

Filed:

Nov 25, 2008

Appl. No.:

12/313969

Inventors:

Philip C. Gevas - Key Biscayne FL, US
Stephen Grimes - Davis CA, US
Stephen L. Karr - Davis CA, US
Susan A. Watson - Nottingham, GB
Dov Michaeli - Larkspur CA, US

International Classification:

A61K 39/00
A61K 33/24
A61P 35/00

US Classification:

4241851

Abstract:

The present invention relates to a combination therapy method for treating gastrin-dependent tumors. The method comprises the immunization of a patient with an anti-gastrin 17 immunogenic composition in combination with the administration of chemotherapeutic agents such as 5-fluorouracil and leucovorin.